Table 3.
Network meta-analysis including KEYNOTE-355 patients assigned to paclitaxel.
| Overall survival | ||||
|---|---|---|---|---|
| Paclitaxel | 1.20 (0.95, 1.51) | 0.94 (0.61, 1.43) | 1.62 (1.05, 2.52) | 2.95 (1.39, 6.25) |
| 0.83 (0.66, 1.05) | Bevacizumab + paclitaxel | 0.78 (0.55, 1.11) | 1.35 (0.93, 1.96) | 2.45 (1.12, 5.39) |
| 1.07 (0.70, 1.63) | 1.28 (0.90, 1.82) | Ixabepilone + bevacizumab | 1.73 (1.21, 2.48) | 3.14 (1.33, 7.47) |
| 0.62 (0.40, 0.95) | 0.74 (0.51, 1.07) | 0.58 (0.40, 0.83) | Nab-paclitaxel + bevacizumab | 1.82 (0.76, 4.34) |
| 0.34 (0.16, 0.72) | 0.41 (0.19, 0.89) | 0.32 (0.13, 0.75) | 0.55 (0.23, 1.31) | Pembrolizumab + paclitaxel |
| Progression-free survival | ||||
|---|---|---|---|---|
| Paclitaxel | 1.82 (1.41, 2.33) | 1.30 (0.85, 1.99) | 2.30 (1.48, 3.55) | 2.70 (1.29, 5.64) |
| 0.55 (0.43, 0.71) | Bevacizumab + paclitaxel | 0.72 (0.51, 1.01) | 1.27 (0.89, 1.80) | 1.49 (0.68, 3.25) |
| 0.77 (0.50, 1.17) | 1.39 (0.99, 1.96) | Ixabepilone + bevacizumab | 1.76 (1.24, 2.49) | 2.07 (0.88, 4.85) |
| 0.44 (0.28, 0.67) | 0.79 (0.55, 1.13) | 0.57 (0.40, 0.81) | Nab-paclitaxel + bevacizumab | 1.18 (0.50, 2.78) |
| 0.37 (0.18, 0.77) | 0.67 (0.31, 1.47) | 0.48 (0.21, 1.14) | 0.85 (0.36, 2.01) | Pembrolizumab + paclitaxel |
Each cell represents the comparison (HR and 95% CrI) of the row treatment vs the column treatment. All bolded values are statistically meaningful at the 0.05 level. Overall survival: deviance information criterion: 7.39; deviance: 3.38. Progression-free survival: Deviance information criterion: 7.62; deviance: 3.62.
HR: Hazard ratio; CrI: Credible interval.